Skip to main content
The Egyptian Journal of Bronchology
Download PDF

Effect of procalcitonin-guided therapy on antibiotic usage in the management of patients with chronic obstructive pulmonary disease with acute exacerbation

Egyptian Journal of Bronchology volume 10, pages 117–125 (2016)Cite this article

Abstract

Background

Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease. In patients with COPD, the clinical manifestations of acute exacerbations due to infectious and noninfectious causes are similar. The differential diagnosis of these two conditions is very important for administering the correct treatment regimen and for avoiding unnecessary antibiotic use, thus reducing the morbidity, mortality, and care-related costs. The aim of this study was to evaluate the diagnostic role of procalcitonin (PCT) and its sensitivity as a marker of bacterial infection in acute exacerbation of chronic obstructive pulmonary disease (AECOPD) patients.

Patients and methods

A total of 53 patients with AECOPD and 30 apparently healthy individuals (control group) were studied. Serum PCT concentrations were measured, and Gram staining of the sputum and sputum culture were performed for the patients with AECOPD. The patients were classified into two subgroups: the bacterial group and the nonbacterial group. The bacterial group included patients with bacterial COPDAE (n=32) and the nonbacterial group included patients with nonbacterial AECOPD (n=21).

Results

The mean level of PCT in patients of the bacterial group (151.65±38.13) was significantly higher than that of the nonbacterial group (60.16±23.98) and control group (36.03 ±16.52) (P<0.01). Other parameters such as inflammatory markers were also measured in the studied groups (total leukocyte count, erythrocyte sedimentation rate in the first and second hours, and C-reactive protein). There was no significant correlation between serum PCT level and the studied parameters in the bacterial group (P> 0.05), and there was no significant correlation between serum PCT level and the studied parameters in the nonbacterial group (P> 0.05). Pulmonary function testing was done for the studied groups and included forced expiratory volume in 1 s (FEV1)/forced vital capacity (%) and FEV1. The association between serum PCT and FEV1% in the two studied group was not significant (P> 0.05).

Conclusion

PCT can be used as a marker for differentiation between bacterial and nonbacterial COPDAE and could be used to guide antibiotic therapy and reduce antibiotic abuse in hospitalized patients with AECOPD.

References

  1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD, 2014. Available at: http://www.goldcopd.org/

  2. Parker CM, Voduc N, Aaron SD, Webb KA, O’Donnell DE. Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur Respir J 2005;26:420–428.

    Article  CAS  Google Scholar 

  3. Barbera JA, Roca J, Ferrer A, Felez MA, Diaz O, Roger N, Rodriguez-Roisin R. Mechanisms of worsening gas exchange during acute exacerbations of chronic obstructive pulmonary disease. Eur Respir J 1997;10:1285–1291.

    Article  CAS  Google Scholar 

  4. Guillemot D, Matson P, Carbon C, Balkau B, Vauzelle-Kervroedan F, Sermet C et al. Trends in antimicrobial use in the community-France, 1981–1992. J Infect Dis 1998;77:492–497.

    Article  Google Scholar 

  5. Gonzalez R, Steiner IF, Sands MA. Antibiotic prescribing for adults with colds, upper respiratory tract infections and bronchitis by ambulatory care physicians. JAMA 1997;278:901–904.

    Article  Google Scholar 

  6. Fridkin SK, Steward CD, Edwards JR, Pryor ER, McGowan JE Jr, Archibald LK et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis 1999;29:245–252.

    Article  CAS  Google Scholar 

  7. Bantar C, Sartori B, Saul M, Salamone F, Vesco M, Morera G. Alarming misuse of antibiotics in a hospital from Argentina. In: Program and abstracts of the 101st General Meeting of the American Society for Microbiology (Orlando, Florida). Washington, DC: American Society for Microbiology; 2001: 17. (abstract A-69)

  8. Beilby I, Marley I, Walkar D, Chamberlain N, Burke M, FIESTA Study Group. Effect of changes in antibiotic prescribing on patient outcomes in a community setting: a natural experiment in Australia. Clin Infect Dis 2002; 34:55–64.

    Article  Google Scholar 

  9. Gross P, Morgan AS, Kinky DE, Weiner M, Gibson GA, Fiahman NO. Impact of a hospital-based antimicrobial management program on clinical and economic outcomes. Gun Infect Dis 2001;33:289–295.

    Article  CAS  Google Scholar 

  10. Shlaes DM, Gerding ON, John JF Jr, Graig WA, Bomstein DC, Duncan RA et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997;18:275–291.

    CAS  Google Scholar 

  11. Barenfanger J, Short MA, Groesch AA. Improved antimicrobial interventions have benefits. J Clin Microbiol 2001;39:2823–2828.

    Article  CAS  Google Scholar 

  12. Zarka V, Valat C, Lemaria E, Boissinot E, Carre P, Besnart JC et al. Procalcitonin and respiratory tract infections. Rev Pneumol Clin 1999;55:365–369.

    CAS  PubMed  Google Scholar 

  13. Ugarte H, Silva E, Mercan D, de Mendonça A, Vincent JL. Procalcitonin used as a marker of infections in the intensive care unit. Crit Care Med 1999;27:498–504.

    Article  CAS  Google Scholar 

  14. Van Leeuwen HJ, Voorbij HA. Procalcitonin concentrations in the diagnosis of acute inflammatory reactions. Ned Tijdschr Geneeskd 2002;146:55–59.

    PubMed  Google Scholar 

  15. Korppi M, Remes S, Heiskanen-Kosma T. Serum procalcitonin concentrations in bacterial pneumonia in children: a negative result in primary healthcare settings. Pediatr Pulmonol 2003;35:56–61.

    Article  Google Scholar 

  16. Baylan O, Albay A, Kisa O, Doganci L. The importance of serum procalcitonin levels in patients with chronic obstructive pulmonary disease exacerbations. Turk J Med Sci 2008;38:139–144.

    Google Scholar 

  17. Brunkhorst FM, Al-Nawas B, Krummenauer F, Forycki ZF, Shah PM. Procalcitonin, C-reactive protein and APACHE II score for risk evaluation in patients with severe pneumonia. Clin Microbiol Infect 2002;8:93–100.

    Article  CAS  Google Scholar 

  18. Global initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD, 2013. Available at: http://www.goldcopd.org/

  19. Polk R. Optimal use of modern antibiotics: emerging trends. Clin Infect Dis 1999;29:264–274.

    Article  CAS  Google Scholar 

  20. Assicot M, Gendred D, Carsin H, Raymound J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993;341:515–518.

    Article  CAS  Google Scholar 

  21. Carrol ED, Thomson AP, Hart CA. Procalcitonin as a marker of sepsis.Int J Antimicrob Agents 2002;20:1–9.

    Article  CAS  Google Scholar 

  22. Mohamed Hoesein FA, Zanen P, Lammers JW. Lower limit of normal or FEV (1)/FVC<0.70 in diagnosing COPD: an evidence-based review. Respir Med 2011;105:907–915.

    Article  Google Scholar 

  23. Linscheid P, Seboek D, Schaer DJ, Zuelwski H, Keller U, Muller B. Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage activated adipocytes. Crit Care Med 2004;32:1715–1721.

    Article  CAS  Google Scholar 

  24. Hactherill M, Tibby SM, Sykes K, Turner C, Murdoch IA. Diagnostic markers of infection: comparison of procalcitonin with C-reactive protein and leucocyte count. Arch Dis Child 1999;81:417–421.

    Article  Google Scholar 

  25. Gendrel D, Bohuon C. Procalcitonin as a marker of bacterial infection. Pediatr Infect Dis J 2000;19:679–687.

    Article  CAS  Google Scholar 

  26. Muller B, White JC, Nylen ES, Snider RH, Becker KL, Habener JF. Ubiquitous expression of the calcitonin-I gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab 2001;86:396–404.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Chest Medicine, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt

    Randa S. Mohammad

  2. Department of Clinical Pathology, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt

    Hisham H. Eissa

  3. Department of Critical Care Medicine, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt

    Abeer S. Mohamed

  4. Department of Chest Medicine, Faculty of Medicine, Helwan University, 27 Omar Bakeer Street, Saint Fatima Square, Helwan, Heliopolis, Cairo, Egypt

    Waleed M. El-Sorougi (MD)

  5. Department of Chest, Embaba Chest Hospital, Cairo, Egypt

    Khaled E. Hassan

Authors
  1. Randa S. Mohammad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Waleed M. El-Sorougi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hisham H. Eissa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Abeer S. Mohamed
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Khaled E. Hassan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Waleed M. El-Sorougi.

Additional information

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mohammad, R.S., El-Sorougi, W.M., Eissa, H.H. et al. Effect of procalcitonin-guided therapy on antibiotic usage in the management of patients with chronic obstructive pulmonary disease with acute exacerbation. Egypt J Bronchol 10, 117–125 (2016). https://doi.org/10.4103/1687-8426.184376

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/1687-8426.184376

Keywords